Compare Stocks: VNRX, KALA, NCEL, and SKYE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KALA KALA BIO	$0.91 -3.7%	$1.54	$0.59 ▼ $1,030.00	$18.29M	-2.26	86,179 shs	114,942 shs
NCEL NLS Pharmaceutics	$3.26 -2.7%	$3.59	$1.83 ▼ $28.03	$17.88M	0.94	12,052 shs	5,389 shs
SKYE Skye Bioscience	$0.42 -17.2%	$0.65	$0.28 ▼ $4.99	$17.62M	2.97	459,041 shs	9.38 million shs
VNRX VolitionRX	$0.50 -7.0%	$1.12	$0.50 ▼ $14.80	$4.64M	1.16	982,752 shs	451,191 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KALA KALA BIO	0.00%	+27.04%	+22.45%	-64.94%	-99.77%
NCEL NLS Pharmaceutics	0.00%	+1.21%	-18.09%	+7.72%	-86.65%
SKYE Skye Bioscience	0.00%	-3.45%	-22.76%	-35.51%	-85.71%
VNRX VolitionRX	0.00%	-30.68%	-51.15%	-76.43%	-96.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KALA KALA BIO	$0.91 -3.7%	$1.54	$0.59 ▼ $1,030.00	$18.29M	-2.26	86,179 shs	114,942 shs
NCEL NLS Pharmaceutics	$3.26 -2.7%	$3.59	$1.83 ▼ $28.03	$17.88M	0.94	12,052 shs	5,389 shs
SKYE Skye Bioscience	$0.42 -17.2%	$0.65	$0.28 ▼ $4.99	$17.62M	2.97	459,041 shs	9.38 million shs
VNRX VolitionRX	$0.50 -7.0%	$1.12	$0.50 ▼ $14.80	$4.64M	1.16	982,752 shs	451,191 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KALA KALA BIO	0.00%	+27.04%	+22.45%	-64.94%	-99.77%
NCEL NLS Pharmaceutics	0.00%	+1.21%	-18.09%	+7.72%	-86.65%
SKYE Skye Bioscience	0.00%	-3.45%	-22.76%	-35.51%	-85.71%
VNRX VolitionRX	0.00%	-30.68%	-51.15%	-76.43%	-96.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KALA KALA BIO	2.00	Hold	$1,158.33	127,161.41% Upside
NCEL NLS Pharmaceutics	2.00	Hold	$23.00	605.52% Upside
SKYE Skye Bioscience	2.20	Hold	$8.00	1,827.25% Upside
VNRX VolitionRX	2.40	Hold	$28.00	5,500.00% Upside

Current Analyst Ratings Breakdown

Latest VNRX, KALA, NCEL, and SKYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	VNRX VolitionRX	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
7/13/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/13/2026	NCEL NLS Pharmaceutics	Laidlaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$23.00
7/10/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/29/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E)
6/24/2026	KALA KALA BIO	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/18/2026	VNRX VolitionRX	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
6/2/2026	VNRX VolitionRX	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KALA KALA BIO	N/A	N/A	N/A	N/A	$12.56 per share	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	$1.59 per share	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$0.62 per share	N/A
VNRX VolitionRX	$1.73M	2.49	N/A	N/A	($5.30) per share	-0.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KALA KALA BIO	-$26.98M	-$96.14	N/A	N/A	N/A	N/A	-1,336.10%	-94.85%	8/17/2026 (Estimated)
NCEL NLS Pharmaceutics	-$8.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	-$55.92M	-$1.27	N/A	N/A	N/A	N/A	-244.83%	-170.10%	N/A
VNRX VolitionRX	-$23.36M	-$0.56	N/A	N/A	N/A	-1,043.12%	N/A	-303.75%	N/A

Latest VNRX, KALA, NCEL, and SKYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	KALA KALA BIO	-$6.00	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	SKYE Skye Bioscience	-$0.29	-$0.27	+$0.02	-$0.3070	N/A	N/A
8/13/2026	Q2 2026	VNRX VolitionRX	-$0.5675	-$0.85	-$0.2825	-$0.85	$0.42 million	$0.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KALA KALA BIO	N/A	7.91	7.91
NCEL NLS Pharmaceutics	N/A	0.76	0.76
SKYE Skye Bioscience	N/A	1.78	1.78
VNRX VolitionRX	N/A	0.30	0.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KALA KALA BIO	24.61%
NCEL NLS Pharmaceutics	N/A
SKYE Skye Bioscience	21.09%
VNRX VolitionRX	8.09%

Insider Ownership

Company	Insider Ownership
KALA KALA BIO	2.24%
NCEL NLS Pharmaceutics	16.40%
SKYE Skye Bioscience	6.20%
VNRX VolitionRX	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KALA KALA BIO	30	19.34 million	18.91 million	Not Optionable
NCEL NLS Pharmaceutics	6	5.35 million	4.47 million	Not Optionable
SKYE Skye Bioscience	11	35.14 million	32.97 million	Optionable
VNRX VolitionRX	80	8.63 million	8.03 million	Not Optionable

VNRX, KALA, NCEL, and SKYE Headlines

Recent News About These Companies

VolitionRX Q2 Earnings Call Highlights

August 16 at 4:03 AM | americanbankingnews.com

VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript

August 14 at 2:00 PM | seekingalpha.com

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

August 13, 2026 | prnewswire.com

VolitionRx Limited (VNRX) Stock Major Holders - Yahoo Finance

August 13, 2026 | finance.yahoo.com

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

August 12, 2026 | prnewswire.com

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

August 11, 2026 | prnewswire.com

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

August 5, 2026 | prnewswire.com

Volition Advances Nu.Q® NETs Platform Towards Commercialization

July 30, 2026 | prnewswire.com

Volitionrx Ltd (VNRX) Stock Forecast & Price Target

July 28, 2026 | investing.com

VolitionRx Shareholders Approve Governance and Capital Changes

July 24, 2026 | theglobeandmail.com

VolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q Execution

July 11, 2026 | finance.yahoo.com

VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test

July 7, 2026 | prnewswire.com

VolitionRx Limited: VolitionRx Announces Collaboration with Sysmex

June 17, 2026 | finanznachrichten.de

VolitionRx partners with Sysmex to optimize Nu.Q® NETs assay

June 17, 2026 | msn.com

VolitionRx Announces Collaboration with Sysmex

June 17, 2026 | prnewswire.com

VolitionRx Announces Pricing of $4.6 Million Public Offering

June 7, 2026 | prnewswire.com

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

June 3, 2026 | prnewswire.com

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

May 27, 2026 | prnewswire.com

VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts

May 24, 2026 | finance.yahoo.com

VolitionRX Earnings Call Balances Breakthroughs and Risks

May 20, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, KALA, NCEL, and SKYE Company Descriptions

KALA BIO NASDAQ:KALA

$0.91 -0.04 (-3.73%)

As of 04:00 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

NLS Pharmaceutics NASDAQ:NCEL

$3.26 -0.09 (-2.69%)

As of 03:59 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Skye Bioscience NASDAQ:SKYE

$0.42 -0.09 (-17.23%)

As of 04:00 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

VolitionRX NYSEAMERICAN:VNRX

$0.50 -0.04 (-6.96%)

As of 04:10 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNRX, KALA, NCEL, and SKYE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNRX, KALA, NCEL, and SKYE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNRX, KALA, NCEL, and SKYE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, KALA, NCEL, and SKYE Company Descriptions

KALA BIO NASDAQ:KALA

NLS Pharmaceutics NASDAQ:NCEL

Skye Bioscience NASDAQ:SKYE

VolitionRX NYSEAMERICAN:VNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNRX, KALA, NCEL, and SKYE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNRX, KALA, NCEL, and SKYE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNRX, KALA, NCEL, and SKYE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, KALA, NCEL, and SKYE Company Descriptions

KALA BIO NASDAQ:KALA

NLS Pharmaceutics NASDAQ:NCEL

Skye Bioscience NASDAQ:SKYE

VolitionRX NYSEAMERICAN:VNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools